We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has handed Infusion Options a warning letter for a slew of GMP deficiencies in compounding sterile products and failing to meet 503B conditions for outsourced compounding operations. Read More
The House Energy and Commerce Committee is scheduled to mark up a bill Wednesday that would encourage the development of abuse-deterrent opioids. Read More
The FDA is proposing to extend review times to enable more communication between the agency and sponsors to increase the number of first cycle approvals for biosimilars. Read More
China is banning wholesalers from selling vaccines after millions of dollars’ worth of illegal products were sold to patients in that country. Read More